Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 9/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | FYN | P06241 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | ALPI | P09923 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | XIAP | P98170 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 4/20 | 0.44 |
| ▸ | NOS1 | P29475 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27339192 | 0.83 | SLC7A5 (0.60) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| SCHEMBL7892985 | 0.80 | SLC7A5 (0.67) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| SCHEMBL10656842 | 0.80 | SLC7A5 (0.67) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| SCHEMBL29809967 | 0.80 | SLC7A5 (0.67) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| SCHEMBL14856009 | 0.80 | SLC7A5 (0.67) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| SCHEMBL18403864 | 0.79 | SLC7A5 (0.65) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| Hydrochloric Acid SCHEMBL7257759 | 0.79 | SLC7A5 (0.65) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| Levodopa SCHEMBL1951331 | 0.76 | SLC7A5 (0.66) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| Levodopa SCHEMBL27813935 | 0.76 | SLC7A5 (0.66) | SLC7A5PTGS1KDM4EUSP2EGFR | |
| SCHEMBL10135632 | 0.76 | SLC7A5 (0.69) | SLC7A5PTGS1KDM4EUSP2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094986-A1 | ANTICANCER DERIVIATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-04-19 | — | — | US | disclosed |
| US-20120094986-A1 | ANTICANCER DERIVIATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094986-A1 | ANTICANCER DERIVIATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | NAMPT, NQO1, NNT | SLC7A5 1625/4885PTGS1 1703/4885KDM4E 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.